» Articles » PMID: 33939034

The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence

Abstract

We analyzed data from 1428 users of the dapivirine vaginal ring, who participated in the MTN-020/ASPIRE phase III trial and subsequent open-label extension MTN-025/HOPE trial, to examine relationships between perceived ring protection, social disclosures, and self-reported ring adherence. In HOPE, 77% perceived the ring to be highly effective, and this view was associated with speaking: (a) to a greater number of people about the study, (b) with other participants, (c) to more people who were in favor of the ring, and (d) to more people whose opinions were valued. Reported adherence was not directly associated with perceived protection but was associated with disclosing to someone who was in favor of the ring. These findings suggest the importance of women's internalized ideas about the protective benefits of the DVR in sharing information about the ring and the importance of social support on adherence.

Citing Articles

Depression Among Pregnant and Breastfeeding Persons Participating in Two Randomized Trials of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis (PrEP) in Malawi, South Africa, Uganda, and Zimbabwe.

Stoner M, Mathebula F, Sedze N, Seyama L, Mohuba R, Fabiano Z AIDS Behav. 2024; 28(7):2264-2275.

PMID: 38526641 PMC: 11531793. DOI: 10.1007/s10461-024-04321-2.


How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis.

Roberts S, Mancuso N, Williams K, Nabunya H, Mposula H, Mugocha C J Int AIDS Soc. 2023; 26(11):e26189.

PMID: 37936551 PMC: 10630658. DOI: 10.1002/jia2.26189.


Adolescent Girls and Young Women's Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis.

Young A, Mancuso N, Atujuna M, Tenza S, Chitukuta M, Kemigisha D AIDS Behav. 2023; 27(12):3941-3951.

PMID: 37392268 PMC: 10598125. DOI: 10.1007/s10461-023-04109-w.

References
1.
Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

2.
Golub S, Fikslin R, Goldberg M, Pena S, Radix A . Predictors of PrEP Uptake Among Patients with Equivalent Access. AIDS Behav. 2019; 23(7):1917-1924. PMC: 6571035. DOI: 10.1007/s10461-018-2376-y. View

3.
Minnis A, Browne E, Boeri M, Agot K, van der Straten A, Ahmed K . Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019; 80(4):394-403. PMC: 6410963. DOI: 10.1097/QAI.0000000000001945. View

4.
Baeten J, Palanee-Phillips T, Brown E, Schwartz K, Soto-Torres L, Govender V . Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016; 375(22):2121-2132. PMC: 4993693. DOI: 10.1056/NEJMoa1506110. View

5.
Golub S, Gamarel K, Rendina H, Surace A, Lelutiu-Weinberger C . From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. 2013; 27(4):248-54. PMC: 3624632. DOI: 10.1089/apc.2012.0419. View